Chandigarh, Mar 18 (PTI) Pharma major Venus Remedies on Monday said it has expanded the reach of its oncology drugs in the Asia Commonwealth of Independent States (CIS) region with marketing authorisations from Ukraine for three cancer drugs-- paclitaxel, oxaliplatin and irinotecan.

Saransh Chaudhary, President, Global Critical Care, Venus Remedies, said, "These marketing approvals mark a significant milestone in our global expansion strategy. We are looking forward to introducing the entire range of our oncology products in Ukraine in due course, thereby contributing to the advancement of healthcare and making a positive impact on people's lives."

Also Read | UKSSSC Recruitment 2024: Vacancies Notified For 1,544 Assistant Teacher Posts, Know How to Apply From March 22 at sssc.uk.gov.in.

With over two decades of presence in the Ukrainian market, the company has 57 product registrations in Ukraine.

"This achievement has further strengthened our position in the international pharmaceutical market. It also exemplifies our dedication to advancing healthcare solutions for diverse populations," said

Also Read | Indian States and Their Formation Dates: Maharashtra Din, Bihar Day, Karnataka Rajyotsava, Kerala Piravi & More - Marking Celebrations of Statehood Days.

Aditi K Chaudhary, President, International Business, Venus Remedies.

Its total volume of exports to Ukraine stands at USD 2.20 million. By strengthening its product portfolio in Ukraine, the company aims to increase this figure by 20 per cent in the next one year, a company statement said.

Venus Remedies is awaiting approval from Ukraine on another 10 applications for marketing authorisations.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)